The k+ uptake regulator trka controls membrane potential, pH homeostasis and multidrug susceptibility in mycobacterium smegmatis

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 7, 2011, Pages 1489-1498

  Castañeda García, Alfredo ^a   Do, Thi Thuy ^a   Blázquez, Jesús ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

Antimicrobials; Drug susceptibility; Mechanisms of resistance; Mycobacteria; Potassium uptake

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; CAPREOMYCIN; CIPROFLOXACIN; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; NOVOBIOCIN; OFLOXACIN; POTASSIUM; PROTEIN TYROSINE KINASE A; RIFAMPICIN; STREPTOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; HOMEOSTASIS; HYPERPOLARIZATION; ION TRANSPORT; MEMBRANE POTENTIAL; MULTIDRUG RESISTANCE; MUTANT; MYCOBACTERIOSIS; MYCOBACTERIUM SMEGMATIS; NONHUMAN; PH HOMEOSTASIS; POTASSIUM TRANSPORT;

AMINO ACID SEQUENCE; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; DRUG RESISTANCE, BACTERIAL; HOMEOSTASIS; HUMANS; HYDROGEN-ION CONCENTRATION; MEMBRANE POTENTIALS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, INSERTIONAL; MYCOBACTERIUM SMEGMATIS; RIFAMPIN; SEQUENCE ALIGNMENT;

EID: 79958856044     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr165     Document Type: Article

References (65)

1. WHO. Global Tuberculosis Control: A Short Update to the 2009 Report. http://www.who.int/tb/publications/global_report/2009/update/en/index. html (23 March 2011, date last accessed).
2. Nguyen L, Thompson CJ. Foundations of antibiotic resistance in bacterial physiology: the mycobacterial paradigm. Trends Microbiol 2006; 14: 304-12.
3. De Rossi E, Aínsa JA, Riccardi G. Role of mycobacterial efflux transporters in drug resistance: an unresolved question. FEMS Microbiol Rev 2006; 30: 36-52.
4. Guerrero A, Cobo J, Fortun J et al. Nosocomial transmission of Mycobacterium bovis resistant to 11 drugs in people with advanced HIV-1 infection. Lancet 1997; 350: 1738-42.
5. Chan ED, Iseman MD. Multidrug-resistant and extensively drug-resistant tuberculosis: a review. Curr Opin Infect Dis 2008; 21: 587-95.
6. Gandhi NR, Nunn P, Dheda K et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010; 375: 1830-43.
7. Takiff HE, Cimino M, Musso MC. Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis. Proc Natl Acad Sci USA 1996; 93: 362-6.
8. Liu J, Takiff HE, Nikaido H. Active efflux of fluoroquinolones in Mycobacterium smegmatis mediated by LfrA, a multidrug efflux pump. J Bacteriol 1996; 178: 3791-5.
9. Montero C, Mateu G, Rodriguez R et al. Intrinsic resistance of Mycobacterium smegmatis to fluoroquinolones may be influenced by new pentapeptide protein MfpA. Antimicrob Agents Chemother 2001; 45: 3387-92.
10. Nash KA. Intrinsic macrolide resistance in Mycobacterium smegmatis in conferred by a novel erm gene, erm(38). Antimicrob Agents Chemother 2003; 47: 3053-60.
11. Li XZ, Zhang L, Nikaido H. Efflux pump-mediated intrinsic drug resistance in Mycobacterium smegmatis. Antimicrob Agents Chemother 2004; 48: 2415-23.
12. Rawat M, Newton GL, Ko M et al. Mycothiol-deficient Mycobacterium smegmatis mutants are hypersensitive to alkylating agents, free radicals, and antibiotics. Antimicrob Agents Chemother 2002; 46: 3348-55.
13. Flores AR, Parsons LM, Pavelka MS Jr. Characterization of novel Mycobacterium tuberculosis and Mycobacterium smegmatis mutants hypersusceptible to b-lactam antibiotics. J Bacteriol 2005; 187: 1892-900.
14. Ren H, Liu J. AsnB is involved in natural resistance of Mycobacterium smegmatis to multiple drugs. Antimicrob Agents Chemother 2006; 50: 250-5.
15. Colangeli R, Haq A, Arcus VL et al. The multifunctional histone-like protein Lsr2 protects mycobacteria against reactive oxygen intermediates. Proc Natl Acad Sci USA 2009; 106: 4414-8.
16. Nguyen HT, Wolff KA, Cartabuke RH et al. A lipoprotein modulates activity of the MtrAB two-component system to provide intrinsic multidrug resistance, cytokinetic control and cell wall homeostasis in Mycobacterium. Mol Microbiol 2010; 76: 348-64.
17. Lew W, Pai M, Oxlade O et al. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med 2008; 149: 123-34.
18. Menzies D, Benedetti A, Paydar A et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med 2009; 6: e1000146.
19. Telenti A, Imboden P, Marchesi F et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993; 341: 647-50.
20. Morlock GP, Plikaytis BB, Crawford JT. Characterization of spontaneous, in vitro-selected, rifampin-resistant mutants of Mycobacterium tuberculosis strain H37Rv. Antimicrob Agents Chemother 2000; 44: 3298-301.
21. Cummings MP, Segal MR. Few amino acid positions in rpoB are associated with most of the rifampin resistance in Mycobacterium tuberculosis. BMC Bioinformatics 2004; 5: 137.
22. Riska PF, Jacobs WR Jr, Alland D. Molecular determinants of drug resistance in tuberculosis. Int J Tuberc Lung Dis 2000; 4: S4-10.
23. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009; 13: 1320-30.
24. Sassetti CM, Boyd DH, Rubin EJ. Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 2003; 48: 77-84.
25. Inderlied CB, Nash KA. Antimycobacterial agents: in vitro susceptibility testing and mechanisms of action and resistance. In: Lorian V, ed. Antibiotics in Laboratory Medicine. Philadelphia, PA: Lippincott Williams and Wilkins, 2005; 155-225.
26. Parish T, Stoker NG. Use of a flexible cassette method to generate a double unmarked Mycobacterium tuberculosis tlyA plcABC mutant by gene replacement. Microbiology 2000; 146 (pt 8): 1969-75.
27. Stover CK, de la Cruz VF, Fuerst TR et al. New use of BCG for recombinant vaccines. Nature 1991; 351: 456-60.
28. Baracca A, Sgarbi G, Solaini G et al. Rhodamine 123 as a probe of mitochondrial membrane potential: evaluation of proton flux through F(0) during ATP synthesis. Biochim Biophys Acta 2003; 1606: 137-46.
29. Resnick M, Schuldiner S, Bercovier H. Bacterial membrane potential analyzed by spectrofluorocytometry. Curr Microbiol 1985; 12: 183-6.
30. Choe S. Potassium channel structures. Nat Rev Neurosci 2002; 3: 115-21.
31. Dosch DC, Helmer GL, Sutton SH et al. Genetic analysis of potassium transport loci in Escherichia coli: evidence for three constitutive systems mediating uptake potassium. J Bacteriol 1991; 173: 687-96.
32. Bossemeyer D, Borchard A, Dosch DC et al. K+-transport protein TrkA of Escherichia coli is a peripheral membrane protein that requires other trk gene products for attachment to the cytoplasmic membrane. J Biol Chem 1989; 264: 16403-10.
33. Rhoads DB, Epstein W. Energy coupling to net K+ transport in Escherichia coli K-12. J Biol Chem 1977; 252: 1394-401.
34. Schlosser A, Hamann A, Bossemeyer D et al. NAD+ binding to the Escherichia coli K(+)-uptake protein TrkA and sequence similarity between TrkA and domains of a family of dehydrogenases suggest a role for NAD+ in bacterial transport. Mol Microbiol 1993; 9: 533-43.
35. Chen P, Bishai WR. Novel selection for isoniazid (INH) resistance genes supports a role for NAD+-binding proteins in mycobacterial INH resistance. Infect Immun 1998; 66: 5099-106.
36. Argyrou A, Jin L, Siconilfi-Baez L et al. Proteome-wide profiling of isoniazid targets in Mycobacterium tuberculosis. Biochemistry 2006; 45: 13947-53.
37. Parra-Lopez C, Lin R, Aspedon A et al. A Salmonella protein that is required for resistance to antimicrobial peptides and transport of potassium. EMBO J 1994; 13: 3964-72.
38. Stumpe S, Bakker EP. Requirement of a large K+-uptake capacity and of extracytoplasmic protease activity for protamine resistance of Escherichia coli. Arch Microbiol 1997; 167: 126-36.
39. Chen YC, Chuang YC, Chang CC et al. A K+ uptake protein, TrkA, is required for serum, protamine, and polymyxin B resistance in Vibrio vulnificus. Infect Immun 2004; 72: 629-36.
40. Andersson DI, Levin BR. The biological cost of antibiotic resistance. Curr Opin Microbiol 1999; 2: 489-93.
41. Billington OJ, McHugh TD, Gillespie SH. Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1999; 43: 1866-9.
42. Mariam DH, Mengistu Y, Hoffner SE et al. Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2004; 48: 1289-94.
43. Gagneux S, Long CD, Small PM et al. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 2006; 312: 1944-6.
44. Epstein W. The roles and regulation of potassium in bacteria. Prog Nucleic Acid Res Mol Biol 2003; 75: 293-320.
45. Mulkidjanian AY, Heberle J, Cherepanov DA. Protons @ interfaces: implications for biological energy conversion. Biochim Biophys Acta 2006; 1757: 913-30.
46. Bakker EP, Mangerich WE. Interconversion of components of the bacterial proton motive force by electrogenic potassium transport. J Bacteriol 1981; 147: 820-6.
47. Nakamura T, Yamamuro N, Stumpe S et al. Cloning of the trkAH gene cluster and characterization of the Trk K(+)-uptake system of Vibrio alginolyticus. Microbiology 1998; 144: 2281-9.
48. Fajardo A, Martinez-Martin N, Mercadillo M et al. The neglected intrinsic resistome of bacterial pathogens. PLoS One 2008; 3: e1619.
49. Tamae C, Liu A, Kim K et al. Determination of antibiotic hypersensitivity among 4,000 single-gene-knockout mutants of Escherichia coli. J Bacteriol 2008; 190: 5981-8.
50. Girgis HS, Hottes AK, Tavazoie S. Genetic architecture of intrinsic antibiotic susceptibility. PLoS One 2009; 4: e5629.
51. Liu A, Tran L, Becket E et al. Antibiotic sensitivity profiles determined with an Escherichia coli gene knockout collection: generating an antibiotic bar code. Antimicrob Agents Chemother 2010; 54: 1393-403.
52. Miesel L, Weisbrod TR, Marcinkeviciene JA et al. NADH dehydrogenase defects confer isoniazid resistance and conditional lethality in Mycobacterium smegmatis. J Bacteriol 1998; 180: 2459-67.
53. Vilcheze C, Weisbrod TR, Chen B et al. Altered NADH/NAD+ ratio mediates coresistance to isoniazid and ethionamide in mycobacteria. Antimicrob Agents Chemother 2005; 49: 708-20.
54. Lee S, Hinz A, Bauerle E et al. Targeting a bacterial stress response to enhance antibiotic action. Proc Natl Acad Sci USA 2009; 106: 14570-5.
55. Su J, Gong H, Lai J et al. The potassium transporter Trk and external potassium modulate Salmonella enterica protein secretion and virulence. Infect Immun 2009; 77: 667-75.
56. Rao M, Streur TL, Aldwell FE et al. Intracellular pH regulation by Mycobacterium smegmatis and Mycobacterium bovis BCG. Microbiology 2001; 147: 1017-24.
57. Follmann M, Becker M, Ochrombel I et al. Potassium transport in Corynebacterium glutamicum is facilitated by the putative channel protein CglK, which is essential for pH homeostasis and growth at acidic pH. J Bacteriol 2009; 191: 2944-52.
58. Thornton G, Wilkinson CR, Toone WM et al. A novel pathway determining multidrug sensitivity in Schizosaccharomyces pombe. Genes Cells 2005; 10: 941-51.
59. Su CC, Li M, Gu R et al. Conformation of the AcrB multidrug efflux pump in mutants of the putative proton relay pathway. J Bacteriol 2006; 188: 7290-6.
60. Pos KM. Drug transport mechanism of the AcrB efflux pump. Biochim Biophys Acta 2009; 1794: 782-93.
61. Eicher T, Brandstätter L, Pos KM. Structural and functional aspects of the multidrug efflux pump AcrB. Biol Chem 2009; 390: 693-9.
62. Rengarajan J, Bloom BR, Rubin EJ. Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages. Proc Natl Acad Sci USA 2005; 102: 8327-32.
63. +-translocating KdpFABC complex from Escherichia coli: a P-type ATPase with unique features. J Bioenerg Biomembr 2007; 39: 397-402.
64. Harms C, Domoto Y, Celik C et al. Identification of the ABC protein SapD as the subunit that confers ATP dependence to the K+-uptake systems TrkH and TrkG from Escherichia coli K-12. Microbiology 2001; 147: 2991-3003.
65. Steel HC, Matlola NM, Anderson R. Inhibition of potassium transport and growth of mycobacteria exposed to clofazimine and B669 is associated with a calcium-independent increase in microbial phospholipase A2 activity. J Antimicrob Chemother 1999; 44: 209-16.